Concepedia

Douglas Bevan

DB

Statistics

Publications

5

Citations

150

H-Index

5

Active since

2010

Affiliations

University of Colorado Boulder(Current)

Cubist Pharmaceuticals (United States)

Douglas Bevan is an author at University of Colorado Boulder specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

2010–2020

5

Publications

5

Development of β-Amino Alcohol Derivatives That Inhibit Toll-like Receptor 4 Mediated Inflammatory Response as Potential Antiseptics

Sherry A. Chavez, Alexander J. Martinko, Corinna Lau et al. · Journal of Medicinal Chemistry · 2011 · 40 citations · Full text

, , +17

Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors

Jing Zhang, Qingyi Yang, Jan Antoinette C. Romero et al. · ACS Medicinal Chemistry Letters · 2015 · 32 citations · Full text

, , +17

Selection, Preparation, and Evaluation of Small-Molecule Inhibitors of Toll-Like Receptor 4

Douglas Bevan, Alexander J. Martinko, Lisa C. Loram et al. · ACS Medicinal Chemistry Letters · 2010 · 28 citations

, , +17

Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors

Jing Zhang, Qingyi Yang, Jason B. Cross et al. · Journal of Medicinal Chemistry · 2015 · 28 citations · Full text

, , +17

Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach

Edwige Lorthiois, James Roache, David Barnes‐Seeman et al. · Journal of Medicinal Chemistry · 2020 · 22 citations · Full text

, , +16

1–5 of 5